aTYR PHARMA INC: 10-Q filed 2022-05-10
What aTYR PHARMA INC reported in its quarterly report filed 2022-05-10 (fiscal Q1 2022): 29 published measures, 59 facts as tagged in accession 0001564590-22-019293.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-05-10
- Fiscal period
- fiscal Q1 2022
- Accession
- 0001564590-22-019293 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All aTYR PHARMA INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 104,776,000 | USD | |
| At 2021-12-31 | 115,537,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 98,550,000 | USD | |
| At 2021-12-31 | 109,301,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 8,324,000 | USD | |
| At 2021-12-31 | 2,336,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -12,153,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -7,151,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -10,119,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -5,827,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 43,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 17,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 1,481,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 24,857,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 14,626,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -23,395,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -384,449,000 | USD | |
| At 2021-12-31 | -372,296,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 433,000 | USD | |
| At 2021-12-31 | 543,000 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -12,378,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -7,202,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 103,117,000 | USD | |
| At 2021-12-31 | 113,569,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 6,269,000 | USD | |
| At 2021-12-31 | 6,013,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,563,000 | USD | |
| At 2021-12-31 | 1,031,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 12,378,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 7,202,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 8,896,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 4,516,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 28,056,249 | shares | |
| At 2021-12-31 | 27,793,035 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 483,730,000 | USD | |
| At 2021-12-31 | 481,832,000 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -759,000 | USD | |
| At 2021-12-31 | -263,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 98,374,000 | USD | |
| At 2021-12-31 | 109,126,000 | USD | |
| At 2021-03-31 | 49,532,000 | USD | |
| At 2020-12-31 | 31,484,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,050,000 | USD | |
| At 2021-12-31 | 1,267,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,145,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 176,000 | USD | |
| At 2021-12-31 | 158,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 3,694,000 | USD | |
| At 2021-12-31 | 4,002,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -12,154,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -7,155,000 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -12,649,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | -7,165,000 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 3,482,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 2,686,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 81,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 121,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 224,000 | USD | 90 |
| 2021-01-01 to 2021-03-31 | 47,000 | USD | 90 |
Inspect the source
- Entity
- aTYR PHARMA INC / CIK 0001339970
- Captured
- 2026-09-20T07:54:07.036Z
- SEC response SHA-256
c3475f065ea6b54c344b2c997462c8932379247c1ed7107b14d14669b6000cf2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001339970.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))